ERBB2 and neoplasm: CAB, a relatively new multi-marker prognostic test entailing five relevant protein biomarkers provides augmented and relevant prognostic information over PREDICT in all patients. Thus, CAB helps optimize treatment for HR+/HER2− EBC patients as its risk stratification is independent of age and clinical parameters and assigns recurrence risk based on tumor biology.